LEADER 01652nam  2200385Ia 450 
001 9910698868803321
005 20090512090534.0
035   $a(CKB)5470000002397176
035   $a(OCoLC)320813893
035   $a(EXLCZ)995470000002397176
100   $a20090512d2006      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for clinical investigators, institutional review boards, and sponsors$b[electronic resource] $eprocess for handling referrals to FDA under 21 CFR 50.54 : additional safeguards for children in clinical investigations
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration,$d[2006]
215   $ai, 9 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 12, 2009).
300   $a"December 2006".
517   $aGuidance for clinical investigators, institutional review boards, and sponsors 
606   $aMedical research personnel$xGovernment policy$zUnited States
606   $aClinical trials$xGovernment policy$zUnited States
606   $aPediatrics$xResearch$xGovernment policy$zUnited States
615  0$aMedical research personnel$xGovernment policy
615  0$aClinical trials$xGovernment policy
615  0$aPediatrics$xResearch$xGovernment policy
712 02$aUnited States.$bFood and Drug Administration.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698868803321
996   $aGuidance for clinical investigators, institutional review boards, and sponsors$93502728
997   $aUNINA